Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methylprednisolone Sodium Succinate

FDA-approved product (injectable, injection), marketed as A-Methapred, Methylprednisolone, Methylprednisolone Sodium Succinate and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Methylprednisolone Sodium Succinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Anemia
  • Asthma
  • Atopic eczema
  • Bursitis
  • Crohn's disease
  • Dermatitis
  • Endocrine system disease
  • Frozen shoulder
  • Inflammation
  • Juvenile idiopathic arthritis
  • Leukemia
  • Lymphoma
  • Multiple sclerosis
  • Osteoarthritis
  • Pneumonia
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, weak (group i); Corticosteroids, combinations for treatment of acne; Glucocorticoids; Corticosteroids for systemic use, combinations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methylprednisolone Sodium Succinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methylprednisolone Sodium Succinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

    NCT00282503 · start 2006-01

    Registered record
    Registry ID
    NCT00282503
    Conditions
    Acute Graft-versus-Host Disease
    Interventions
    Methoxsalen+ECP, Methylprednisolone; Ecp
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-01
    Completion
    Not recorded
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Graft-versus-Host Disease
    InterventionMethoxsalen+ECP, Methylprednisolone; Ecp
    PhasePhase 3
    Registry statusTerminated

  • Phase I/II Thymus Transplantation With Immunosuppression #950

    NCT00579527 · start 2005-12-19

    Registered record
    Registry ID
    NCT00579527
    Conditions
    DiGeorge Anomaly; Complete DiGeorge Anomaly; Complete Atypical DiGeorge Anomaly; Complete DiGeorge Syndrome; Complete Atypical DiGeorge Syndrome
    Interventions
    Cultured Thymus Tissue for Implantation (CTTI); Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation; Blood Draw; Rabbit anti-thymocyte globulin; Cyclosporine; Tacrolimus; Methylprednisolone or Prednisolone; Daclizumab; Mycophenolate mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2005-12-19
    Completion
    2017-12-31
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiGeorge Anomaly; Complete DiGeorge Anomaly; Complete Atypical DiGeorge Anomaly; Complete DiGeorge Syndrome +1 more
    InterventionCultured Thymus Tissue for Implantation (CTTI); Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation; Blood Draw; Rabbit anti-thymocyte globulin +5 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Myfortic vs. Cellcept in Kidney Transplant Recipients

    NCT00533624 · start 2004-12

    Registered record
    Registry ID
    NCT00533624
    Conditions
    End Stage Renal Disease
    Interventions
    Mycophenolate Sodium Delayed Release Tablets; Mycophenolate Mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2004-12
    Completion
    2006-02
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease
    InterventionMycophenolate Sodium Delayed Release Tablets; Mycophenolate Mofetil
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

    NCT00022126 · start 2002-11

    Registered record
    Registry ID
    NCT00022126
    Conditions
    Leukemia
    Interventions
    asparaginase; cyclophosphamide; cyclosporine; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; mercaptopurine; methotrexate; methylprednisolone; pegaspargase; thioguanine; vincristine sulfate; allogeneic bone marrow transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-11
    Completion
    2006-04
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionasparaginase; cyclophosphamide; cyclosporine; cytarabine +11 more
    PhasePhase 2
    Registry statusCompleted

  • Absorption of Corticosteroids in Children With Juvenile Dermatomyositis

    NCT00004357 · start 1997-09

    Registered record
    Registry ID
    NCT00004357
    Conditions
    Vasculitis, Hypersensitivity; Connective Tissue Diseases; Dermatomyositis; Vasculitis
    Interventions
    Methylprednisolone; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-09
    Completion
    2008-02
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasculitis, Hypersensitivity; Connective Tissue Diseases; Dermatomyositis; Vasculitis
    InterventionMethylprednisolone; Prednisolone
    PhasePhase 2
    Registry statusCompleted